Please assess the completion status of the following clinical trial:

Trial Title: Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients with confirmed HER-2 positive , non-operable locally advanced or metastatic breast cancer~* All patients must have received at least 1 but no more than 2 prior anti HER2 based regimens including at least 1 regimen containing Trastuzumab.~* All patients must have at least one measurable lesion as defined by RECIST criteria.~* All patients must have documented progressive disease following the last line of therapy before entering the study~* ECOG Performance status ≤ 1~Exclusion Criteria:~* Patients with known CNS metastasis which are: symptomatic or require treatment for symptom control and/or growing~* Prior treatment with any HSP90 or HDAC inhibitor~* Impaired cardiac function~* Acute or chronic liver or renal disease~* Patients who are currently receiving treatment with any medication which has a relative risk of prolonging the QTc interval or inducing Torsades de Pointes and cannot be switched or discontinued to an alternative drug prior to commencing AUY922~* Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention~* Patients who do not have either an archival tumor sample available or are unwilling to have a fresh tumor sample collected at baseline.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AUY922 + Trastuzumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).